China considers mixing COVID-19 vaccines to boost protection rate
- Wall Street ends with broad sell-off on spiking inflation fears
- Bitcoin Falls as Musk Says Tesla (TSLA) Will Suspend Vehicle Purchases Using Bitcoin, Citing Use of Fossil Fuels in Mining
- Fed Has Already Changed its Policy Due to Inflation, Market Gambling Fears - Dick Bove
- U.S. consumer prices post largest gain since 2009 as inflation ramps up
- Bill Ackman said has he been working on a transaction for Pershing Square Tontine (PSTH) for months
FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed China flag in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
BEIJING (Reuters) -China's top disease control official has said the country is formally considering mixing COVID-19 vaccines as a way of further boosting vaccine efficacy.
Available data shows Chinese vaccines lag behind others including Pfizer and Moderna in terms of efficacy, but require less stringent temperature controls during storage.
Giving people doses of different vaccines is one way to improve vaccines that "don't have very high rates of protection", Gao Fu, the director of the Chinese Centers for Disease Control and Prevention, said on Saturday, without specifying whether he was referring to foreign or domestic vaccines
"Inoculation using vaccines of different technical lines is being considered," Gao told a conference in the Chinese city of Chengdu.
Gao said that taking steps to "optimise" the vaccine process including changing the number of doses and the length of time between doses was a "definite" solution to efficacy issues.
Two injections of a vaccine developed by China's Sinovac Biotech, when given shorter than three weeks apart, was 49.1% effective based on data from a Phase III trial in Brazil, below the 50% threshold set by World Health Organization, according to a paper published by Brazilian researchers on Sunday ahead of peer review.
But data from a small subgroup showed that the efficacy rate increased to 62.3% when the doses were given at intervals of three weeks and longer. The overall efficacy rate for the vaccine was slightly above 50% in the trial.
China has developed four domestic vaccines approved for public use and a fifth for smaller-scale emergency use. An official said on Saturday that the country will likely produce 3 billion doses by the end of the year.
No detailed efficacy data has been released on vaccines made by China's Sinopharm. It has said two vaccines developed by its units are 79.4% and 72.5% effective respectively, based on interim results.
Both vaccine makers have presented data on their COVID-19 vaccines indicating levels of efficacy in line with those required by WHO, a WHO panel said in March.
China has shipped millions of its vaccines abroad, and officials and state media have fiercely defended the shots while calling into question the safety and logistics capabilities of other vaccines.
"The global vaccine protection rate test data are both high and low," Gao told state tabloid Global Times on Sunday.
"How to improve the protection rate of vaccines is a problem that requires global scientists to consider," Gao said, adding that mixing vaccines and adjusting immunisation methods are solutions that he had proposed.
Gao also rejected claims by some media reports that he said Chinese COVID-19 vaccines have a low protection rate, telling Global Times that it was "a complete misunderstanding."
(Reporting by Cate Cadell; Additional writing by Ryan Woo; Editing by David Evans and Michael Perry)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cuban tanker en route to Venezuela reports missing sailor at sea -document
- Dollar holds gains on inflation, kiwi boosted by reopening
- Taiwanese cities tighten restrictions after COVID-19 cases rise
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!